Donald R. Dengel, Ph.D., professor in the School of Kinesiology and director of the Laboratory of Integrative Human Physiology, recently co-authored an article titled “Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: impact of Anastrozole on bone mineral density and visceral adipose tissue’” that was published in Clinical Endocrinology.

The study found that Anastrozole, an aromatase inhibitor that has been used in males with short stature to delay bone maturation, significantly reduced bone age advancement while advancing bone age without adversely affecting bone mineral density or visceral adipose tissue in children with congenital adrenal hyperplasia. The objective was to evaluate Anastrozole’s effect on bone mineral density and visceral adipose tissue in children with congenital adrenal hyperplasia. The paper concluded that longitudinal studies of Anastrozole in children with congenital adrenal hyperplasia are needed to validate these findings.